- Home
- MCRB vs SURG Comparison
MCRB vs SURG Comparison
Compare MCRB & SURG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- SURG
- Stock Information
- Founded
- MCRB 2010
- SURG 2006
- Country
- MCRB United States
- SURG United States
- Employees
- MCRB N/A
- SURG N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- SURG Advertising
- Sector
- MCRB Health Care
- SURG Consumer Discretionary
- Exchange
- MCRB Nasdaq
- SURG Nasdaq
- Market Cap
- MCRB 72.0M
- SURG 59.4M
- IPO Year
- MCRB 2015
- SURG N/A
- Fundamental
- Price
- MCRB $7.05
- SURG $2.75
- Analyst Decision
- MCRB Hold
- SURG Strong Buy
- Analyst Count
- MCRB 5
- SURG 1
- Target Price
- MCRB $73.67
- SURG $8.75
- AVG Volume (30 Days)
- MCRB 93.5K
- SURG 226.8K
- Earning Date
- MCRB 05-07-2025
- SURG 05-13-2025
- Dividend Yield
- MCRB N/A
- SURG N/A
- EPS Growth
- MCRB N/A
- SURG N/A
- EPS
- MCRB 8.98
- SURG N/A
- Revenue
- MCRB N/A
- SURG $40,029,467.00
- Revenue This Year
- MCRB N/A
- SURG $103.68
- Revenue Next Year
- MCRB N/A
- SURG $51.08
- P/E Ratio
- MCRB $0.84
- SURG N/A
- Revenue Growth
- MCRB N/A
- SURG N/A
- 52 Week Low
- MCRB $6.53
- SURG $1.05
- 52 Week High
- MCRB $30.60
- SURG $4.38
- Technical
- Relative Strength Index (RSI)
- MCRB 38.95
- SURG 48.39
- Support Level
- MCRB $7.32
- SURG $3.01
- Resistance Level
- MCRB $7.86
- SURG $3.17
- Average True Range (ATR)
- MCRB 0.63
- SURG 0.27
- MACD
- MCRB 0.10
- SURG -0.04
- Stochastic Oscillator
- MCRB 28.89
- SURG 27.17
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About SURG SurgePays Inc.
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.